Drug Profile
Fibrinogen three-component sealant - PPL Therapeutics
Alternative Names: Factor I/factor IIa/factor XIII; Fibrinogen/thrombin/factor XIII; Three component fibrin sealant - PPL TherapeuticsLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator PPL Therapeutics PLC
- Class Antihaemorrhagics; Blood coagulation factors; Blood proteins; Serine endopeptidases
- Mechanism of Action Blood coagulation factor replacements; Factor XIII stimulants; Fibrinogen receptor agonists; Fibrinogen replacements; Fibrinogen stimulants; Thrombin replacements; Thrombin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Blood coagulation disorders; Wounds
Most Recent Events
- 20 Apr 2001 Discontinued - Preclinical for Coagulation disorders in United Kingdom (Topical)
- 20 Apr 2001 Discontinued - Preclinical for Wounds in United Kingdom (Topical)
- 21 Nov 2000 Preclinical development for Wounds in United Kingdom (Topical)